A Monograph for the Integrative Clinician

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine

Integrative & Functional Medicine Physician

Medical Disclaimer: This monograph is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Heat-based interventions carry real risks including burns, scarring, infection, cardiovascular strain, hypotension, teratogenicity, and drug interactions. Direct moxibustion deliberately produces a thermal skin injury and must not be self-administered without training; it is contraindicated in diabetes, peripheral neuropathy, peripheral vascular disease, immunosuppression, keloid tendency, and over the face or major vessels. Clinical hyperthermia in oncology is a supervised medical procedure requiring calibrated thermal dosimetry and is in no way substitutable by consumer sauna, infrared, moxa, or herbal use. Consult a qualified healthcare provider before beginning any heat therapy — particularly if you have cardiovascular disease, are pregnant or may become pregnant, have uncontrolled blood pressure, take anticoagulants, or use medications affecting thermoregulation or sensation.

CHAPTER ONE

Foundations: Convergence, Baseline, Fever, and Thermal Dose

“Give me the power to produce fever, and I will cure all disease.”

— Attributed to Parmenides, c. 500 BCE

1.1 A Convergent Tradition in Search of an Accurate Mechanism

The therapeutic use of heat appears, independently derived, in nearly every ancient medical system: Hippocratic hot baths, Roman thermae, Japanese onsen, Finnish sauna, Russian banya, Turkish hammam, Korean jjimjilbang, the Mesoamerican temazcal, the Indigenous North American sweat lodge, Ayurvedic svedana, and the East Asian burning of mugwort at defined body points. Convergence across cultures that never communicated is prima facie evidence that heat produces effects the body reliably registers as beneficial. The task of modern medicine is neither to sentimentalize these traditions nor to discard them, but to test their empirical claims and reconstruct their mechanisms accurately.

1.2 The Collapse of the 98.6°F Standard

Wunderlich's mid-nineteenth-century compilation established 37°C as the human norm.[1] The value is now known to be historically contingent. Protsiv and colleagues (2020), analysing 677,423 measurements across 157 years of birth cohorts from Union Army veterans, NHANES, and Stanford STRIDE, demonstrated a monotonic decline of approximately 0.03°C per birth decade, placing the modern mean oral temperature nearer 36.4–36.6°C (97.5–97.9°F).[2] Mackowiak (1992) and Obermeyer (2017) reached concordant conclusions.[3,4] Frameworks reading every sub-98.6°F measurement as “deficient vitality” or evidence of a “chronically hypothermic” population are refuted by population data.

1.3 Fever as the Template

Fever is a regulated elevation of the hypothalamic set-point, evolutionarily conserved across vertebrates at considerable metabolic cost. Elevated core temperature enhances phagocytosis, accelerates lymphocyte proliferation, augments leukocyte trafficking through heat-induced vascular adhesion molecule expression, and potentiates interferon and heat shock protein signalling.[5] The febrile response is the body's own hyperthermia protocol.

1.4 Thermal Dose: The Discipline the Field Imposed on Itself

No concept is more central to thermal medicine than thermal dose. Heat is not a binary exposure but a dose with two dimensions — temperature and time — and until these were unified the field could not compare one treatment with another.

Sapareto and Dewey (1984) resolved this with the cumulative equivalent minutes at 43°C (CEM43), converting any time–temperature history into a single equivalent number of minutes at 43°C.[6] The formulation rests on the biphasic Arrhenius relationship of cell killing, with a breakpoint near 43°C: below it each 1°C increase roughly quadruples the rate of thermal damage; above it each 1°C roughly doubles it. Because in vivo heating is heterogeneous, practice reports percentile-indexed variants, CEM43T90 being the most conservative.

Three implications govern everything that follows. A hyperthermia treatment that does not report thermal dose is uninterpretable, and a trial that does not achieve adequate dose has tested nothing. The same physical agent spans an enormous therapeutic range: a sauna session, fever-range whole-body hyperthermia, a tumour at 43°C, a moxa cone on the skin, and thermal ablation at 60°C differ not in kind but in accumulated dose. And thermal dose supplies the quantitative backbone of hormesis: low doses adapt, high doses ablate, and the window between is narrow and must be measured.

1.4.1 A thermal dose ladder

It is useful to place the modalities of this monograph on a single scale. The values below are approximate and illustrative rather than measured, and are offered to convey orders of magnitude:

The ladder makes explicit what prose can obscure: the difference between a sauna and an ablation is not a difference of philosophy but of arithmetic, and direct moxibustion sits far higher on it than any other traditional practice in this text.

CHAPTER TWO

Herbal Thermogenesis: Reconstructing “Warming” at the Molecular Level

2.1 Capsaicin and the Discovery of the Thermosensor

The 1997 cloning of the capsaicin receptor by Caterina and colleagues transformed the pharmacology of warming herbs from metaphor into molecular science.[7] TRPV1 is a polymodal, calcium-permeable cation channel gated by noxious heat above roughly 43°C, by low pH, and by exogenous vanilloids; its discovery contributed to the 2021 Nobel Prize awarded to David Julius. It is expressed on nociceptive afferents, adipocytes, gastrointestinal epithelium, vascular smooth muscle, and immune cells.

The coincidence of thresholds deserves emphasis. TRPV1 opens at approximately 43°C — the same breakpoint at which the Arrhenius relationship of thermal cell killing changes slope, and the reference temperature Sapareto and Dewey chose for CEM43. The molecule the body uses to sense dangerous heat is calibrated to the temperature at which heat becomes dangerous. Capsaicin is, pharmacologically, a molecular impersonation of 43°C.

2.1.1 The thermogenic cascade

TRPV1 activation on sensory afferents evokes reflex sympathetic outflow, releasing norepinephrine at adipose nerve terminals; norepinephrine engages β3-adrenergic receptors on brown and beige adipocytes, elevating cAMP, driving lipolysis, and inducing UCP-1, which dissipates the mitochondrial proton gradient as heat.[8] Baskaran and colleagues (2016) demonstrated a complementary pathway in which dietary capsaicin induces browning of white adipose tissue via TRPV1-dependent calcium influx and sirtuin-1-mediated deacetylation of PPARγ and PRDM-16 — abolished in TRPV1-knockout animals.[9]

2.1.2 The magnitude problem

The meta-analysis of Ludy, Moore and Mattes (2012) concluded that capsaicin and capsiate augment energy expenditure and fat oxidation, but that the magnitude is small — on the order of 50 kcal per day at intakes of 2–4 mg.[10] Whiting and colleagues (2012) concurred.[11] Capsaicin is a real thermogenic and a plausible adjunct; it is not a metabolic transformation in a capsule.

2.1.3 Where the evidence is strongest

Derry and colleagues (2017), in a Cochrane review of eight double-blind randomized trials enrolling 2,488 patients, established that the high-concentration 8% capsaicin patch produces clinically meaningful relief in postherpetic neuralgia and HIV-associated neuropathy, with a number-needed-to-treat of roughly 10–12.[12] Lv and colleagues (2015) found in the China Kadoorie Biobank that near-daily spicy-food consumption was associated with 14% lower total mortality — an association, not a proof.[13]

2.1.4 Safety

Oral capsaicin at thermogenic doses commonly produces heartburn, epigastric pain and diarrhoea limiting adherence, and carries antiplatelet activity relevant to anticoagulated clients. At least two independent case reports document acute myocardial infarction following ingestion of high-dose cayenne pepper slimming pills in young men without cardiovascular risk factors, with angiography in one case showing patent coronary arteries and implicating vasospasm rather than atherosclerotic occlusion.[14,56] Causation in single cases is never established, but the mechanism — sympathomimetic activity producing coronary vasospasm — is biologically coherent and the signal is worth disclosing to any client considering high-dose supplementation.

2.2 Ginger: Anti-Inflammatory First, Thermogenic Second

Ginger's constituents act principally as anti-inflammatory and antioxidant agents through inhibition of Akt phosphorylation and NF-κB translocation, suppression of COX-2 and lipoxygenase, reduction of TNF-α, IL-1β and IL-6, and Nrf2-mediated upregulation of antioxidant defences.[15,16] Ernst and Pittler (2000) found ginger effective for postoperative nausea, seasickness and hyperemesis gravidarum, with effect sizes for postoperative nausea comparable to metoclopramide.[17] Meta-analytic evidence in osteoarthritis shows modest consistent benefit with a superior gastrointestinal safety profile relative to NSAIDs.[18]

2.3 The Bounded Claim

Capsaicin and ginger deliver genuine anti-inflammatory, antioxidant and modest thermogenic effects through defined molecular targets. They do not detoxify cells or expel intracellular waste. Expressed in the units of Chapter 1, the CEM43 delivered by a meal of chilli is indistinguishable from zero; its effects are receptor-mediated, not thermal.

CHAPTER THREE

Sauna, Hormesis, and the Heat Shock Paradox

3.1 The Finnish Cohort Evidence

Laukkanen and colleagues (2015) followed 2,315 middle-aged Finnish men in the Kuopio Ischemic Heart Disease cohort for a median 20.7 years.[19] Relative to once-weekly users, men bathing 4–7 times weekly showed 63% lower risk of sudden cardiac death, 50% lower cardiovascular mortality and 40% lower all-cause mortality, in a dose-dependent gradient most pronounced with sessions of 19 minutes or longer at 79°C or above. Later analyses documented reduced stroke,[20] reduced dementia and Alzheimer's disease,[21] and reduced incident hypertension.[22] A comprehensive review appears in Laukkanen, Laukkanen and Kunutsor (2018).[23]

These are observational data. Reverse causation cannot be excluded, and in a country where sauna is near-universal, frequency may proxy for leisure, income and social integration; correspondence in JAMA Internal Medicine cautioned explicitly against causal reading.[24] The dose-response gradient, consistency across mechanistically distinct endpoints, and biological plausibility strengthen the inference without completing it.

3.2 Hormesis and the Heat Shock Response

Sauna raises core temperature by 1–2°C, a mild proteotoxic stress answered by heat shock factor-1 activation and induction of HSP70 and HSP90 — chaperones that refold denatured proteins, tag irreparable ones for disposal, suppress apoptotic caspase activation and modulate autophagy. Layered onto this are eNOS upregulation, reduced arterial stiffness, parasympathetic shift, and cardiac demand comparable to moderate exercise.

3.3 The Heat Shock Paradox and Thermotolerance

Here a complication must be introduced that popular accounts of sauna and heat shock proteins invariably omit. Heat shock proteins are cytoprotective — and cancer cells are cells.

The same HSP70 and HSP90 induction that protects a cardiomyocyte also protects a malignant cell from subsequent thermal injury. This is thermotolerance: a sublethal heat exposure renders tissue transiently resistant to a second exposure, the refractory period lasting on the order of days. Thermotolerance is why hyperthermia in oncology is delivered weekly or twice weekly rather than daily. HSP90 in particular chaperones a client list rich in oncogenic signalling proteins, which is why HSP90 inhibitors are an anticancer drug class.

The paradox is real but not fatal, and its resolution is dose and context. At the low CEM43 of sauna bathing, HSP induction serves proteostasis, vascular function and stress resilience. At the high CEM43 of oncologic hyperthermia, HSP induction is an adversary to be scheduled around, and simultaneously an ally, since HSPs released from dying tumour cells chaperone tumour antigens and enhance dendritic cell presentation — the mechanism Repasky and colleagues surveyed in arguing that temperature deserves standing as a variable in tumour immunology.[32] Heat shock proteins are neither good nor bad; they are a stress response whose valence depends on dose and tissue.

3.4 Far-Infrared and Waon Therapy

Waon therapy uses 15 minutes in a far-infrared dry sauna at 60°C followed by 30 minutes of supine rest under blankets — a lower thermal load tolerable for patients too fragile for Finnish sauna. Miyata and colleagues (2008) conducted a prospective multicenter case-control study of 188 patients with NYHA class II–IV chronic heart failure across ten Japanese hospitals; the Waon arm showed significant improvement in NYHA class, plasma BNP, six-minute walk distance and cardiothoracic ratio without serious adverse events.[25] Five-year follow-up by Kihara and colleagues (2009) reported reduced combined cardiac death and rehospitalization.[26] Masuda and colleagues (2005) documented symptomatic recovery in two prednisolone-refractory chronic fatigue syndrome patients — a case report, not a trial — with parallel work on chronic pain and mild depression.[27,28,29] The evidence derives predominantly from one research group and awaits Western replication.

3.5 Safety: What the Enthusiast Literature Omits

Elevated maternal core temperature in the first trimester is a recognized teratogenic exposure associated with neural tube defects; sauna, hot tub and infrared cabin use should be avoided in early pregnancy. Scrotal heating transiently suppresses spermatogenesis. The combination of alcohol and sauna is the dominant contributor to sauna-associated sudden death in Finnish forensic series and is absolutely contraindicated. Orthostatic hypotension after heat-induced vasodilation is a fall risk in older adults and those on antihypertensives, diuretics or alpha-blockers. Unstable angina, recent myocardial infarction, severe aortic stenosis and decompensated heart failure warrant medical clearance.

CHAPTER FOUR

Hyperthermia in Oncology: History, Randomized Evidence, and the Lesson of Failure

“Those diseases which medicines do not cure, iron cures; those which iron cannot cure, fire cures; and those which fire cannot cure are to be reckoned wholly incurable.”

— Hippocrates, Aphorisms VII.87

4.1 Two Historical Foundations

4.1.1 Coley's toxins

The modern history of deliberate fever in oncology begins with William B. Coley, who after the death of a young patient in 1891 reviewed hospital records and found accounts of inoperable sarcomas regressing after erysipelas.[30] Building on earlier observations by Busch and Fehleisen, Coley injected sarcoma patients first with live Streptococcus pyogenes and subsequently with a heat-killed preparation of S. pyogenes and Serratia marcescens, producing high fever and, in a documented subset, durable tumour regression. He is reasonably called the father of cancer immunotherapy. His work also illustrates the field's enduring difficulty: the response was unpredictable and the dose uncontrolled — the very problems thermal dosimetry was later invented to solve.

4.1.2 Wagner-Jauregg and the only Nobel Prize for fever

In 1917 the Austrian psychiatrist Julius Wagner-Jauregg inoculated patients suffering general paresis of the insane — tertiary neurosyphilis, then uniformly fatal — with Plasmodium vivax, producing sustained fevers of 40–41°C before terminating the malaria with quinine. Remission rates were sufficient that he received the 1927 Nobel Prize in Physiology or Medicine, the only Nobel awarded for fever therapy and the first to a psychiatrist.[31]

The episode reassures and alarms in equal measure. It is the strongest historical demonstration that induced hyperthermia can alter the natural history of a serious disease. It is also a caution: malariotherapy killed roughly 15% of those who received it, and was abandoned not because it failed but because penicillin achieved the same end without the mortality. The acceptable risk of a heat intervention is entirely a function of what else is available.

4.2 Biological Rationale

Mild heating (39–41°C) increases tumour blood flow and oxygenation; because ionizing radiation requires oxygen to generate DNA-damaging free radicals, heat acts as a radiosensitizer, and the same perfusion increase improves drug delivery to hypoxic cores. At 41–43°C direct cytotoxicity follows from protein denaturation, inhibition of DNA repair enzymes and membrane disruption — injuries to which malignant cells are preferentially vulnerable because their chaotic low-flow vasculature cannot dissipate heat.[32]

4.3 The Landmark Randomized Evidence

4.3.1 Dutch Deep Hyperthermia Trial

van der Zee and colleagues (2000) randomized 358 patients with locally advanced pelvic tumours to radiotherapy alone or with regional hyperthermia.[33] In cervical carcinoma, complete response rose from 57% to 83%, three-year pelvic control from 41% to 61%, and three-year overall survival from 27% to 51%. Twelve-year follow-up confirmed durable survival advantage without increased late toxicity.[34]

4.3.2 Melanoma

Overgaard and colleagues (1995) treated 134 recurrent or metastatic melanoma lesions with radiotherapy alone or with hyperthermia at 43°C for 60 minutes; two-year local control rose from 28% to 46%.[35] Melanoma is among the most radioresistant of human cancers, which makes the result mechanistically informative.

4.3.3 Soft tissue sarcoma

EORTC 62961-ESHO 95 randomized 341 patients with localized high-risk soft tissue sarcoma to neoadjuvant chemotherapy with or without regional hyperthermia at 42°C. Long-term outcomes reported by Issels and colleagues (2018) showed a 35% reduction in risk of local progression or death, with median local progression-free survival of 67.3 versus 29.2 months, and improved overall survival at a median 11.3 years.[36]

4.3.4 Hyperthermic intraperitoneal chemotherapy — a corrected account

HIPEC delivers heated cytotoxic drug directly to the peritoneal cavity at operation. OVHIPEC-1 (van Driel et al., 2018) randomized 245 patients with stage III epithelial ovarian cancer to interval cytoreductive surgery with or without HIPEC; median overall survival was 45.7 versus 33.9 months.[37]

A Korean counter-trial is often cited as simply negative, but the definitive publication tells a more interesting story. Lim and colleagues (2022), publishing in JAMA Surgery, randomized 184 women at two Korean centres and found that HIPEC did not improve progression-free survival overall in newly diagnosed stage III–IV disease — but that benefit was observed in the subgroup undergoing interval cytoreductive surgery after neoadjuvant chemotherapy.[38] That subgroup is precisely the OVHIPEC-1 population. The two trials, read carefully, do not simply contradict one another; they converge on a narrower indication than either headline suggests, and diverge where the populations diverge.

This is a more demanding but more accurate reading, and it does not resolve the deeper problem: neither trial can isolate the thermal contribution from regional drug delivery, since both compare heated intraperitoneal chemotherapy against no intraperitoneal chemotherapy. Further randomized trials, including OVHIPEC-2 and trials in recurrent disease, are ongoing. HIPEC is classified in this text as an area of active and unresolved investigation.

4.4 The Lesson of Failure: RTOG 81-04 and Quality Assurance

The most instructive trial in thermal oncology is one that failed. From 1981 the Radiation Therapy Oncology Group randomized 300 patients with superficial measurable tumours to radiotherapy with or without hyperthermia at 42.5°C for 60 minutes. Complete response was 28% with radiotherapy and 32% with radiotherapy plus heat — not significant — and the trial was widely read as evidence that hyperthermia does not work.[39]

The companion report by Perez and colleagues (1989) established the actual explanation. Only 56% of tumours smaller than 3 cm, and 36% of lesions larger than 3 cm, received what the investigators considered adequate therapy; equipment limitations meant only a small minority of treatments achieved the protocol thermal objective at all.[40] The negative result was a delivery failure, not a biological refutation. The response was formal quality-assurance guidelines from the RTOG and ESHO, under which the field's subsequent positive trials were conducted.

Three conclusions follow. A hyperthermia trial that does not verify thermal dose delivery tests nothing. Negative trials must be interrogated for adequacy of heating before being read as biological inefficacy. And the divergence between European and North American adoption of hyperthermia is explained less by differing biology than by differing quality assurance and reimbursement history.

4.5 The Honest Counter-Evidence

Hyperthermia's benefit is heterogeneous. In the Dutch trial, rectal cancer showed no survival benefit and the bladder local-control gain eroded over time.[33] A Japanese randomized trial in locally advanced cervical cancer improved complete response but not survival.[41] The network meta-analysis of Datta and colleagues (2019) confirms benefit robust for cervical carcinoma and superficial recurrences but inconsistent elsewhere, and heavily dependent on achieved thermal dose.[42] The MATTERS trial established safety of repeated whole-body hyperthermia at 41.5°C with chemotherapy in metastatic pancreatic cancer,[43] and modulated electro-hyperthermia improved outcomes in a Phase III cervical trial in a resource-constrained setting.[44]

4.6 The Indispensable Caveat

Clinical hyperthermia is a monitored medical procedure with calibrated thermal dosimetry, often under sedation, delivered by trained personnel in accredited centres. It bears no legitimate resemblance to a consumer sauna, an infrared cabin, a moxa cone or a cup of ginger tea, and its evidence must never be borrowed to market such products.

CHAPTER FIVE

Whole-Body Hyperthermia in Psychiatry; Moxibustion, Direct and Indirect

5.1 Heat and the Depressed Brain

Janssen and colleagues (2016), in a randomized, double-blind, sham-controlled trial in JAMA Psychiatry, treated 34 adults with major depressive disorder with a single session of whole-body hyperthermia.[45] The active group showed significant reduction in Hamilton Depression Rating Scale scores emerging within one week and persisting six weeks after one treatment. The proposed mechanism implicates thermosensitive serotonergic projections from the dorsal raphe nucleus and modulation of inflammatory signalling. The sample was small and advertisement-recruited; replication is underway. The finding is a lineal descendant of Wagner-Jauregg's observation that fever alters the course of psychiatric disease.

5.2 Moxibustion: Two Millennia of Thermal Medicine

“When a disease may not be treated by acupuncture, moxibustion is advised.”

— Huangdi Neijing (The Yellow Emperor's Inner Classic), c. 100 BCE

Moxibustion — the burning of dried mugwort (Artemisia argyi or A. vulgaris) at defined body points — is one of the two principal therapeutic tools of classical Chinese medicine. The Huangdi Neijing, compiled around 100 BCE, and the older Mawangdui silk manuscripts recovered from Han-dynasty tombs describe it in detail; in the earliest strata moxibustion may in fact predate needling, since combustible mugwort was more available and less injurious than the sharpened bian stones that preceded metal needles.[46,47]

The practice carried enormous social and clinical validity for two thousand years. Sun Simiao, the seventh-century “King of Medicine,” prescribed moxibustion at BL43 for chronic and difficult diseases; the Song dynasty standardized its teaching through the Imperial Medical Service; it became Okyu in Japanese Kampo and a cornerstone of Korean medicine. Its practitioners advanced a defensible empirical claim: that localized heat applied to specific tissue produces reproducible physiological and symptomatic effects.

5.3 Direct Moxibustion: The Controlled Burn

Moxibustion is commonly discussed as though it were a single technique, and almost always as indirect heating. That framing omits its older and more thermally intense form. The distinction matters, because direct moxibustion is the only widely practised traditional therapy that delivers a thermal dose plausibly sufficient to induce local heat shock protein expression.

5.3.1 What it is

In direct moxibustion (Japanese chokusetsu-kyū, 直接灸; Korean jikjeopgu, 直接灸) a cone of refined moxa floss, classically the size of a grain of rice or smaller, is placed directly on the skin at an acupoint and ignited, burning down to the surface. The classical literature distinguishes scarring moxibustion (瘢痕灸), in which the cone is permitted to burn fully and produce a deliberate small blister and eventual scar, from non-scarring moxibustion, in which the cone is extinguished or removed as the patient reports heat, leaving transient erythema and at most a pinpoint superficial burn that heals without permanent mark. Contemporary practice, in Japan and Korea especially, overwhelmingly uses the non-scarring form, often with cones a few millimetres across, repeated in series of five to fifteen at a single point.

5.3.2 Why the burn is the point

Practitioners of direct moxa have always maintained that the small burn is therapeutic rather than incidental. The modern mechanistic literature gives this claim more support than one might expect, and the thermal dose framework of Chapter 1 explains why.

Jiang and colleagues (2016), analysing the thermal determinants of moxibustion efficacy, report that skin temperature during moxibustion ranges from approximately 34°C to 57°C depending on the material used, the distance from the skin and the presence of an insulating divider, and map this range onto the activation thresholds of the thermosensitive TRP vanilloid channels: TRPV4 at above 27–35°C, TRPV3 at above 34–38°C, TRPV1 at 43°C and above, and TRPV2 at 52°C and above.[48] The authors conclude that peak moxibustion temperature should exceed 40°C for efficacy, and that the effect is determined principally by activation of TRPV1 and TRPV2.

This is the key to the distinction. Indirect moxibustion — a stick held above the skin, a cone on a slice of ginger or salt, a far-infrared lamp — typically occupies the warm end of that range, engaging TRPV3 and TRPV4 and, at best, brushing the TRPV1 threshold. Direct moxibustion, with burning material in contact with skin, reaches the upper end and is the only common form that reliably crosses the TRPV2 threshold at 52°C. In the language of thermal dose, indirect moxa delivers a local CEM43 near the floor of the scale; direct moxa delivers a small but genuinely non-trivial local dose. That the practitioners who developed these techniques could not measure temperature, yet arrived empirically at a graded family of methods spanning precisely the range of the thermosensitive channels, is a striking instance of pre-scientific calibration.

Corroborating this receptor account, Li and Jiang (2015) reported that moxibustion raised the thermal pain threshold in wild-type mice but that the effect was attenuated by the TRPV1 antagonist capsazepine and absent in TRPV1-knockout animals — receptor-dependence of the kind that distinguishes a mechanism from an association.[49]

5.3.3 The heat shock and sterile injury hypothesis

Two consequences follow from delivering a supra-threshold local thermal dose. The first is heat shock protein induction: sublethal thermal stress in keratinocytes and dermal cells activates heat shock factor-1 and upregulates HSP70, the same proteostatic response described in Chapter 3, but here concentrated in a small volume of tissue rather than diffused across the body. The second is that a controlled micro-burn is a sterile injury, releasing damage-associated molecular patterns that recruit innate immune cells, initiate a local inflammatory and reparative cascade, and — in the classical framing — constitute the “warming and tonifying” effect for which direct moxa was prized in the treatment of chronic and deficiency conditions.

It must be stated plainly that this remains a mechanistic hypothesis supported principally by preclinical and inferential work rather than by human trials designed to test it. Reviews of moxibustion mechanism consistently identify HSP70 induction and TRPV activation among the plausible pathways, but there is no randomized human trial demonstrating that direct moxibustion's clinical effects are mediated by heat shock protein expression. What can be said with confidence is that direct moxa delivers a thermal dose in the range where HSP induction is expected, whereas indirect moxa largely does not — which makes the hypothesis worth testing and makes the two techniques worth distinguishing in trials, as they usually are not.

5.3.4 Risks

Direct moxibustion deliberately injures skin, and the risks are correspondingly real: burns deeper than intended, blistering, secondary infection, scarring and keloid formation. It is contraindicated in diabetes, peripheral neuropathy and peripheral vascular disease, where impaired sensation and healing convert a controlled burn into an uncontrolled one; in immunosuppression; over the face, major vessels, mucous membranes and the abdomen or lumbosacral region in pregnancy; and in keloid-prone individuals. It should not be self-administered without training. These are not theoretical cautions: the technique's safety depends entirely on the operator's control of a variable — how long the cone burns — that no instrument is measuring.

5.4 The Clinical Evidence

The strongest contemporary evidence concerns breech presentation. Coyle, Smith and Peat, in Cochrane systematic reviews (2012, updated 2023), found that moxibustion at BL67 (Zhiyin, lateral fifth toe) increases cephalic version.[50,51] The 2023 update, covering 13 trials and 2,181 women, reports moderate-certainty evidence that moxibustion plus usual care probably reduces non-cephalic presentation at birth compared with sham plus usual care (RR 0.74, 95% CI 0.58–0.95), while probably producing little to no effect on caesarean section rate (RR 0.84, 95% CI 0.68–1.04). For irritable bowel syndrome, chemotherapy-induced nausea and pain syndromes, evidence is suggestive but constrained by small samples and the difficulty of blinding a therapy producing visible smoke and felt warmth.[52,53]

A methodological point deserves emphasis: the great majority of moxibustion trials do not report thermal dose, do not specify whether direct or indirect technique was used, and do not measure skin temperature. Given that the mechanistic literature identifies temperature as the determining variable, this is the same omission that produced RTOG 81-04. Moxibustion research is, in this respect, where hyperthermic oncology stood in 1985.

5.5 A Modern Social History: Kim Nam-soo and the Korean Moxibustion Dispute

The claim that moxibustion is a socially valid phenomenon rather than a museum curiosity is best illustrated not by antiquity but by a legal conflict of the last two decades. Kim Nam-soo, born around 1915, practised acupuncture and moxibustion in South Korea for more than sixty years and became the country's best-known traditional practitioner, treating generals, celebrities, business figures and at least one president. He was certified as an acupuncturist in 1983 by an administrative court, which accepted his then fifty-seven years of experience together with a practitioner's certificate issued under Japanese colonial administration.

The certification did not extend to moxibustion. Under the Korean Medical Service Act, moxibustion may be performed only by licensed Korean Medicine doctors trained in accredited colleges, and Kim's practice of it was therefore unlicensed. He closed his clinic in late 2008 under pressure from the Korean Oriental Medicine Association; his teaching institute, which had trained several thousand lay practitioners in moxibustion, was held to have issued certificates without legal standing; and he was subsequently indicted. In 2010 the Constitutional Court considered a petition to permit long-practising traditional therapists to be licensed. It rejected the petition — but narrowly: five of nine justices voted against the existing law, one short of the six required to strike it down, and the court's spokesman characterized the outcome as a message to the government about revising an antiquated statute.

The episode is worth a monograph's attention for three reasons. It demonstrates that moxibustion retains sufficient public demand and perceived efficacy in a technologically advanced society to generate a constitutional case, which is not the profile of an abandoned folk remedy. It illustrates the genuine regulatory problem the practice poses: direct moxibustion inflicts a deliberate burn, and burns require training, sterile technique and judgement about contraindications — the professional bodies' position that it should be restricted to licensed clinicians is a defensible patient-safety argument, not merely guild protection. And it shows that the fight was specifically about moxibustion rather than acupuncture, precisely because burning is riskier than needling. The controversy is, in the end, a dispute about thermal dose conducted in the language of licensure.

5.6 From Moxa Smoke to the Infrared Lamp

The far-infrared mineral lamp — the TDP lamp (Teding Diancibo Pu) — was developed in China to deliver moxibustion's thermal benefit without its combustion, heating a mineral-coated plate to roughly 400–500°C and emitting far-infrared in the 2–25 micrometre band, penetrating soft tissue 2–4 cm.

The evidence must be stated precisely. Gao and colleagues (2024), in a systematic review and meta-analysis of fifteen trials comprising approximately 1,568 participants, examined electroacupuncture combined with TDP for peripheral facial paralysis. The overall effective rate did not differ significantly from comparator treatments (RR 1.05, 95% CI 0.97–1.12, p = 0.226); the recovery rate did favour the combination (RR 1.14, 95% CI 1.05–1.24, p = 0.002).[54] This is a positive but partial result that cannot isolate the lamp's contribution from concurrent electroacupuncture. The proprietary claim that the mineral coating emits therapeutically unique wavelengths surpassing a generic far-infrared emitter remains unverified.

The framework of this chapter permits a sharper statement than is usually offered. The infrared lamp is an excellent substitute for indirect moxibustion, which it matches in thermal range while eliminating smoke, ash and fire risk. It is not a substitute for direct moxibustion, because it does not reach the tissue temperatures at which the controlled micro-burn, TRPV2 activation and local heat shock response occur. A clinic that replaces all its moxa with lamps has cleanly modernized one half of the tradition and quietly discontinued the other. Whether that trade is worthwhile is an empirical question that the absence of dose-reporting in moxibustion trials has so far prevented anyone from answering.

CHAPTER SIX

Heated Stone Massage, Synthesis, and the Grammar of Therapeutic Heat

6.1 Heated Stone Massage

Heated basalt stones warmed to 54–60°C appear in Chinese, Ayurvedic and Indigenous North American lineages. No large randomized trial has tested the modality against defined clinical endpoints, and its plausibility must therefore be constructed from its components — a construction that must be done honestly.

Massage therapy is frequently described as having systematic-review support for chronic low back pain. It does not, at least not in the sense usually implied. The Cochrane review of Furlan and colleagues (2015) concluded that the authors had very little confidence that massage is an effective treatment for low back pain: improvements in pain were observed only at short-term follow-up, functional improvement only in sub-acute and chronic cases compared with inactive controls, and the quality of evidence was rated low to very low throughout.[55] Any account of heated stone massage that rests on massage's supposed evidence base is therefore resting on less than it assumes.

What remains defensible is narrower. Superficial heat is an established physiotherapeutic modality for musculoskeletal pain and muscle spasm; heat increases fascial extensibility and plausibly improves the mechanical efficiency of manual work; and the ritual, touch and relaxation elements plausibly contribute parasympathetic activation. Heated stone massage is therefore best described as a low-risk comfort intervention with a coherent physiological rationale and no direct outcome evidence — not as an evidence-supported treatment. The principal hazard is thermal burn over areas of impaired sensation or circulation.

6.2 What the Evidence Supports

Controlled thermal stress produces reproducible, mechanistically defined responses: endothelial nitric oxide synthesis; heat shock protein induction and proteostatic maintenance; autonomic rebalancing; enhanced leukocyte trafficking and immunosurveillance; reduced inflammatory signalling; adipose browning via UCP-1; and, at oncologic thermal dose, radiosensitization, chemosensitization and direct cytotoxicity. Heat is not one therapy but a family of interventions sharing a hormetic logic and separated by orders of magnitude of CEM43.

Evidence is strongest for regional hyperthermia in cervical carcinoma, melanoma and soft tissue sarcoma (randomized controlled trials); whole-body hyperthermia in major depression (sham-controlled trial); Finnish sauna for cardiovascular and neurocognitive protection (large dose-responsive cohorts); far-infrared Waon therapy in chronic heart failure (multicentre prospective data); high-concentration topical capsaicin for neuropathic pain (Cochrane-grade); moxibustion at BL67 for cephalic version (Cochrane-grade); and ginger for nausea. It is contested for HIPEC in ovarian cancer, where the thermal contribution is not isolable. It is moderate for dietary capsaicin and ginger as anti-inflammatory agents, and preliminary for heated stone massage, for the distinctive claims of the TDP mineral plate, and for the heat shock hypothesis of direct moxibustion.

6.3 What the Evidence Does Not Support

The literature does not support — and the responsible clinician must not assert — that consumer-grade thermal interventions cure cancer, detoxify cells, expel intracellular waste, or heal through vital force, quantum energy or unmeasured electromagnetic vibration. When such frameworks lead patients to substitute thermal folk protocols for evidence-based care, they cause real harm.

6.4 The Grammar of Therapeutic Heat

Ancient traditions possessed the correct nouns of therapeutic heat — sauna, moxa, hot stone, warming herb — and observed their effects with genuine acuity. What they lacked was the grammar connecting intervention to outcome, and the arithmetic of dose. They wrote “heat expels toxins” where the accurate sentence reads “controlled thermal stress at a specified cumulative equivalent dose induces heat shock proteins, activates thermosensitive TRP channels, upregulates endothelial nitric oxide and recruits hormetic adaptation.” The therapy was right; the explanation was wrong; the dose was unmeasured. The task of integrative medicine is to preserve the noun, correct the grammar, and supply the number.

CHAPTER SEVEN

The Defense: Specialist Questions and the Author's Answers

Q. You now claim direct moxibustion's burn induces heat shock proteins. Is that demonstrated, or is it a mechanism you find attractive?

A. It is a hypothesis with converging indirect support, not a demonstrated fact, and I have labelled it as such in the text rather than letting the reader infer otherwise. What is demonstrated is the following chain of premises: that moxibustion skin temperatures range up to roughly 57°C and that direct contact technique occupies the upper part of that range; that TRPV1 and TRPV2 activate at 43°C and 52°C respectively, so direct moxa crosses thresholds indirect moxa does not; that moxibustion's antinociceptive effect is attenuated by TRPV1 antagonism and absent in TRPV1-knockout mice; and that sublethal thermal stress in the 43–52°C range is a canonical inducer of HSF-1 and HSP70 in mammalian cells generally.

What is missing is the step that would close the argument: a human trial of direct moxibustion measuring local HSP expression and correlating it with clinical outcome. To my knowledge that trial has not been done. I would therefore say the heat shock account of direct moxa is the most plausible mechanism currently available and the one I would design a study to test, but that anyone asserting it as established is overstating. The value of saying so precisely is that it converts a traditional claim into a falsifiable research question, which is what this monograph is for.

Q. Your Korean case study is a story about licensure, not physiology. Why does it belong in a scientific monograph?

A. Because the monograph's argument is not purely physiological, and pretending otherwise would be a different kind of dishonesty. My claim throughout is that traditional thermal practices contain a valid empirical core deserving accurate mechanistic reconstruction. That claim has a sociological component: it matters whether a practice persists because people find it useful or persists as inherited habit.

The Korean dispute supplies unusually clean evidence on that question. A therapy that generates a constitutional case, a national newspaper debate, several thousand lay trainees and a five-to-four vote among supreme jurists in a country with world-class conventional medicine is not a museum artifact. That is data about persistence under conditions where alternatives are freely available.

It belongs here for a second reason that is squarely physiological. The dispute was specifically about moxibustion and not acupuncture, and the reason is that burning is riskier than needling. The professional bodies' safety argument is, translated, an argument about uncontrolled thermal dose administered by operators without training in burn management. That is precisely the concern this monograph raises in its own voice in the safety section. I did not include the case to advocate for Kim Nam-soo; I included it because both sides of that argument are correct about different things, and a reader deciding whether to seek direct moxa should understand why.

Q. Your own field's most cited failure, RTOG 81-04, produced a null result. You attribute this to quality assurance. Is that not the unfalsifiable reasoning you condemn elsewhere?

A. This is the sharpest question in the set, because the structure of my argument does resemble the special pleading I criticize. Three features distinguish them. The quality-assurance explanation was not constructed retrospectively: Perez and colleagues reported the delivery failure themselves, documenting that only a minority of treatments achieved the protocol thermal objective. It made a testable prediction — that trials under adequate dosimetry would show benefit — subsequently confirmed in the Dutch, sarcoma and melanoma trials. And I do not apply it universally: I accept the rectal and bladder nulls in the Dutch trial as genuine, and classify HIPEC as contested.

The discipline separating explanation from excuse is that thermal dose is independently measurable. Where dosimetry documents the failure, it is diagnosis rather than special pleading. I apply the same standard against my own case in Chapter 5, where I note that moxibustion trials overwhelmingly fail to report thermal dose and are therefore vulnerable to exactly the error that produced RTOG 81-04 — which is a concession, not a defence.

APPENDIX

Declared Limitations of the Evidence

Every clinical recommendation in this monograph is graded to the strength of the source supporting it. Where that source is a single research group, an unreplicated trial, a case report, or mechanistic inference rather than human outcome evidence, the reader is entitled to know. The following limitations qualify specific claims made in the preceding chapters and should be read alongside them.

A.1 Mechanism Asserted Ahead of Human Evidence

•  The heat shock protein account of direct moxibustion (§5.3.3) is a mechanistic hypothesis. It rests on measured moxibustion skin temperatures, the known activation thresholds of TRPV1 and TRPV2, receptor-dependence demonstrated in knockout animals, and the established behaviour of the heat shock response in mammalian cells. No human trial has measured local heat shock protein expression against clinical outcome, and until one does the account should be treated as the most plausible available mechanism rather than a demonstrated one.

•  The claim that the TDP mineral plate confers benefit beyond a generic far-infrared emitter of the same wavelength band is not endorsed anywhere in this text. It has not been independently verified, and a head-to-head trial would settle it.

A.2 Evidence Resting on a Single Group or a Single Study

•  The Waon therapy literature derives predominantly from one research group at Kagoshima University and awaits independent Western replication. Its protocol is specific and its results should not be generalized to infrared exposure of other durations or temperatures.

•  The Masuda report on chronic fatigue syndrome describes two patients. It is a case report, is cited as such, and carries the evidentiary weight of a case report.

•  The whole-body hyperthermia trial in major depressive disorder enrolled 34 advertisement-recruited participants. The design is rigorous — randomized, double-blind, sham-controlled — but the sample is small and the finding unreplicated.

A.3 Contested and Unresolved Questions

•  Hyperthermic intraperitoneal chemotherapy in ovarian cancer is contested. Neither OVHIPEC-1 nor the Korean trial isolates the thermal contribution from regional drug delivery, because both compare heated intraperitoneal chemotherapy against no intraperitoneal chemotherapy. A trial comparing heated against normothermic intraperitoneal delivery would be required to answer the question this monograph is about.

•  Hyperthermia’s oncologic benefit is site-specific and dose-dependent. It is robust for cervical carcinoma, melanoma and soft tissue sarcoma; it was absent for rectal cancer and eroded over time in bladder cancer in the same trial that established it elsewhere.

A.4 Structural Limits of the Field

•  Sauna cohort data are observational throughout. No randomized trial on hard cardiovascular endpoints exists, and none is likely, because heat cannot be blinded. Reverse causation and lifestyle confounding cannot be excluded, and the dose-response gradient and mechanistic plausibility strengthen the inference without completing it.

•  The great majority of moxibustion trials do not report thermal dose, do not specify whether direct or indirect technique was used, and do not measure skin temperature. Since the mechanistic literature identifies temperature as the determining variable, this limits interpretation across the entire moxibustion literature and reproduces the methodological failure that produced a decade of uninterpretable hyperthermia trials.

•  Heated stone massage has no direct outcome evidence. It is presented in this text as a low-risk comfort intervention with a coherent physiological rationale, and should not be represented as an evidence-supported treatment.

A.5 Historical and Biographical Material

•  Dates and details in the account of the Korean moxibustion dispute (§5.5) are drawn from contemporaneous press reporting rather than primary legal records, and should be treated as journalistic rather than archival.

A.6 A Note on Sources

Every citation in the reference list has been checked against a primary source — the publisher’s page, the PubMed record, or the issuing body — rather than reproduced from memory or from a secondary citation. Two records are only partially confirmed and are declared here: the digital object identifier for Miyata and colleagues (2008) could not be independently confirmed and has been omitted rather than reproduced unverified, though volume, issue and page range are confirmed; and Unschuld’s Huang Di Nei Jing Su Wen is a monograph rather than an indexed article, cited for historical context only, with no clinical claim resting upon it.

References

1. Wunderlich CRA. Das Verhalten der Eigenwärme in Krankheiten. Leipzig: Otto Wigand; 1868.

2. Protsiv M, Ley C, Lankester J, Hastie T, Parsonnet J. Decreasing human body temperature in the United States since the Industrial Revolution. eLife. 2020;9:e49555. doi:10.7554/eLife.49555. https://elifesciences.org/articles/49555

3. Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6°F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA. 1992;268(12):1578–1580.

4. Obermeyer Z, Samra JK, Mullainathan S. Individual differences in normal body temperature: longitudinal big data analysis of patient records. BMJ. 2017;359:j5468. doi:10.1136/bmj.j5468. https://www.bmj.com/content/359/bmj.j5468

5. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15(6):335–349. doi:10.1038/nri3843.

6. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800. doi:10.1016/0360-3016(84)90379-1.

7. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–824. doi:10.1038/39807.

8. Saito M, Yoneshiro T. Capsinoids and related food ingredients activating brown fat thermogenesis and reducing body fat in humans. Curr Opin Lipidol. 2013;24(1):71–77. doi:10.1097/MOL.0b013e32835a4f40.

9. Baskaran P, Krishnan V, Ren J, Thyagarajan B. Capsaicin induces browning of white adipose tissue and counters obesity by activating TRPV1 channel-dependent mechanisms. Br J Pharmacol. 2016;173(15):2369–2389. doi:10.1111/bph.13514. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.13514

10. Ludy MJ, Moore GE, Mattes RD. The effects of capsaicin and capsiate on energy balance: critical review and meta-analyses of studies in humans. Chem Senses. 2012;37(2):103–121. doi:10.1093/chemse/bjr100. https://academic.oup.com/chemse/article/37/2/103/273510

11. Whiting S, Derbyshire E, Tiwari BK. Capsaicinoids and capsinoids. A potential role for weight management? A systematic review of the evidence. Appetite. 2012;59(2):341–348. doi:10.1016/j.appet.2012.05.015.

12. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1(1):CD007393. doi:10.1002/14651858.CD007393.pub4. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007393.pub4/full

13. Lv J, Qi L, Yu C, et al. Consumption of spicy foods and total and cause specific mortality: population based cohort study. BMJ. 2015;351:h3942. doi:10.1136/bmj.h3942. https://www.bmj.com/content/351/bmj.h3942

14. Sayin MR, Karabag T, Dogan SM, Akpinar I, Aydin M. A case of acute myocardial infarction due to the use of cayenne pepper pills. Wien Klin Wochenschr. 2012;124(7-8):285–287. doi:10.1007/s00508-012-0163-8.

15. Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, Li HB. Bioactive compounds and bioactivities of ginger (Zingiber officinale Roscoe). Foods. 2019;8(6):185. doi:10.3390/foods8060185. https://www.mdpi.com/2304-8158/8/6/185

16. Ballester P, Cerdá B, Arcusa R, Marhuenda J, Yamedjeu K, Zafrilla P. Effect of ginger on inflammatory diseases. Molecules. 2022;27(21):7223. doi:10.3390/molecules27217223. https://www.mdpi.com/1420-3049/27/21/7223

17. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84(3):367–371. doi:10.1093/oxfordjournals.bja.a013442. https://academic.oup.com/bja/article/84/3/367/264600

18. Bartels EM, Folmer VN, Bliddal H, et al. Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2015;23(1):13–21. doi:10.1016/j.joca.2014.09.024.

19. Laukkanen T, Khan H, Zaccardi F, Laukkanen JA. Association between sauna bathing and fatal cardiovascular and all-cause mortality events. JAMA Intern Med. 2015;175(4):542–548. doi:10.1001/jamainternmed.2014.8187. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2130724

20. Kunutsor SK, Khan H, Zaccardi F, Laukkanen T, Willeit P, Laukkanen JA. Sauna bathing reduces the risk of stroke in Finnish men and women: a prospective cohort study. Neurology. 2018;90(22):e1937–e1944. doi:10.1212/WNL.0000000000005606. https://www.neurology.org/doi/10.1212/WNL.0000000000005606

21. Laukkanen T, Kunutsor S, Kauhanen J, Laukkanen JA. Sauna bathing is inversely associated with dementia and Alzheimer's disease in middle-aged Finnish men. Age Ageing. 2017;46(2):245–249. doi:10.1093/ageing/afw212. https://academic.oup.com/ageing/article/46/2/245/2654230

22. Zaccardi F, Laukkanen T, Willeit P, Kunutsor SK, Kauhanen J, Laukkanen JA. Sauna bathing and incident hypertension: a prospective cohort study. Am J Hypertens. 2017;30(11):1120–1125. doi:10.1093/ajh/hpx102.

23. Laukkanen JA, Laukkanen T, Kunutsor SK. Cardiovascular and other health benefits of sauna bathing: a review of the evidence. Mayo Clin Proc. 2018;93(8):1111–1121. doi:10.1016/j.mayocp.2018.04.008.

24. Kivimäki M, Virtanen M, Ferrie JE. The link between sauna bathing and mortality may be noncausal. JAMA Intern Med. 2015;175(10):1718. doi:10.1001/jamainternmed.2015.3426.

25. Miyata M, Kihara T, Kubozono T, et al. Beneficial effects of Waon therapy on patients with chronic heart failure: results of a prospective multicenter study. J Cardiol. 2008;52(2):79–85.

26. Kihara T, Miyata M, Fukudome T, et al. Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol. 2009;53(2):214–218. doi:10.1016/j.jjcc.2008.11.005.

27. Masuda A, Kihara T, Fukudome T, Shinsato T, Minagoe S, Tei C. The effects of repeated thermal therapy for two patients with chronic fatigue syndrome. J Psychosom Res. 2005;58(4):383–387. doi:10.1016/j.jpsychores.2004.11.005.

28. Masuda A, Koga Y, Hattanmaru M, Minagoe S, Tei C. The effects of repeated thermal therapy for patients with chronic pain. Psychother Psychosom. 2005;74(5):288–294. doi:10.1159/000086319.

29. Masuda A, Nakazato M, Kihara T, Minagoe S, Tei C. Repeated thermal therapy diminishes appetite loss and subjective complaints in mildly depressed patients. Psychosom Med. 2005;67(4):643–647. doi:10.1097/01.psy.0000171812.67767.8f.

30. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–158. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1888599/

31. The Nobel Prize in Physiology or Medicine 1927: Julius Wagner-Jauregg. Nobel Prize Outreach. https://www.nobelprize.org/prizes/medicine/1927/wagner-jauregg/facts/

32. Repasky EA, Evans SS, Dewhirst MW. Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res. 2013;1(4):210–216. doi:10.1158/2326-6066.CIR-13-0118. https://aacrjournals.org/cancerimmunolres/article/1/4/210/

33. van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA; Dutch Deep Hyperthermia Group. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet. 2000;355(9210):1119–1125. doi:10.1016/S0140-6736(00)02059-6.

34. Franckena M, Stalpers LJ, Koper PC, et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008;70(4):1176–1182. doi:10.1016/j.ijrobp.2007.07.2348.

35. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet. 1995;345(8949):540–543. doi:10.1016/s0140-6736(95)90463-8.

36. Issels RD, Lindner LH, Verweij J, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4(4):483–492. doi:10.1001/jamaoncol.2017.4996. https://jamanetwork.com/journals/jamaoncology/fullarticle/2672386

37. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240. doi:10.1056/NEJMoa1708618. https://www.nejm.org/doi/full/10.1056/NEJMoa1708618

38. Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY; HIPEC for Ovarian Cancer Collaborators. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374–383. doi:10.1001/jamasurg.2022.0143. https://jamanetwork.com/journals/jamasurgery/fullarticle/2789683

39. Perez CA, Pajak T, Emami B, Hornback NB, Tupchong L, Rubin P. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology Group. Am J Clin Oncol. 1991;14(2):133–141.

40. Perez CA, Gillespie B, Pajak T, Hornback NB, Emami B, Rubin P. Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a report by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1989;16(3):551–558. doi:10.1016/0360-3016(89)90471-9.

41. Harima Y, Ohguri T, Imada H, et al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer. Int J Hyperthermia. 2016;32(7):801–808. doi:10.1080/02656736.2016.1213430.

42. Datta NR, Stutz E, Gomez S, Bodis S. Efficacy and safety evaluation of the various therapeutic options in locally advanced cervix cancer: a systematic review and network meta-analysis of randomized clinical trials. Int J Radiat Oncol Biol Phys. 2019;103(2):411–437. doi:10.1016/j.ijrobp.2018.09.037.

43. Brancato L, Gorbaslieva I, Rudenko O, et al. The MATTERS trial: safety and tolerability of whole-body hyperthermia at 41.50°C in combination with chemotherapy in metastatic cancer patients. Cancer Res Commun. 2026. doi:10.1158/2767-9764.CRC-25-0660. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12869149/

44. Minnaar CA, Kotzen JA, Ayeni OA, et al. The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: early results from a phase III randomised controlled trial. PLoS One. 2019;14(6):e0217894. doi:10.1371/journal.pone.0217894. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584021/

45. Janssen CW, Lowry CA, Mehl MR, et al. Whole-body hyperthermia for the treatment of major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(8):789–795. doi:10.1001/jamapsychiatry.2016.1031. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2521478

46. Huang B, Zhang Y, Huang H, et al. Moxibustion in early Chinese medicine and its relation to the origin of meridians: a study on the unearthed literatures. Evid Based Complement Alternat Med. 2017;2017:8242136. doi:10.1155/2017/8242136. https://onlinelibrary.wiley.com/doi/10.1155/2017/8242136

47. Unschuld PU. Huang Di Nei Jing Su Wen: Nature, Knowledge, Imagery in an Ancient Chinese Medical Text. Berkeley: University of California Press; 2003.

48. Jiang J, Wang X, Wu X, Yu Z. Analysis of factors influencing moxibustion efficacy by affecting heat-activated transient receptor potential vanilloid channels. J Tradit Chin Med. 2016;36(2):255–260. doi:10.1016/S0254-6272(16)30036-X.

49. Li J, Jiang J. Role of transient receptor potential vanilloid subtype 1 in the increase of thermal pain threshold by moxibustion. J Tradit Chin Med. 2015;35(5):583–587.

50. Coyle ME, Smith CA, Peat B. Cephalic version by moxibustion for breech presentation. Cochrane Database Syst Rev. 2012;5:CD003928. doi:10.1002/14651858.CD003928.pub3. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003928.pub3/full

51. Coyle ME, Smith C, Peat B. Cephalic version by moxibustion for breech presentation. Cochrane Database Syst Rev. 2023;5(5):CD003928. doi:10.1002/14651858.CD003928.pub4. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003928.pub4/full

52. Yang Y, Rao K, Zhan K, et al. Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2022;10:1022145. doi:10.3389/fpubh.2022.1022145. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801330/

53. Lee MS, Choi TY, Park JE, Lee SS, Ernst E. Moxibustion for cancer care: a systematic review and meta-analysis. BMC Cancer. 2010;10:130. doi:10.1186/1471-2407-10-130.

54. Gao HW, Xia QC, Li ZH, Chen W, Lu Y. Efficacy analysis of electroacupuncture plus TDP in the treatment of peripheral facial paralysis: a systematic review and meta-analysis. Front Neurol. 2024;15:1450312. doi:10.3389/fneur.2024.1450312. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1450312/full

55. Furlan AD, Giraldo M, Baskwill A, Irvin E, Imamura M. Massage for low-back pain. Cochrane Database Syst Rev. 2015;2015(9):CD001929. doi:10.1002/14651858.CD001929.pub3. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001929.pub3/full

56. Sogut O, Kaya H, Gokdemir MT, Sezen Y. Acute myocardial infarction and coronary vasospasm associated with the ingestion of cayenne pepper pills in a 25-year-old male. Int J Emerg Med. 2012;5:5. doi:10.1186/1865-1380-5-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284873/

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of clinical experience. A graduate of the University of Arizona Center for Integrative Medicine under the Andrew Weil Fellowship, he holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with additional certification in medical acupuncture (UCLA). He specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and more than twenty peer-reviewed articles.

Professional: www.yoonhangkim.com      |      Clinical: www.directintegrativecare.com